It’s one thing to read about poor cancer survival rates and it’s another to have it applied to your own life.

If you ever read about an aggressive form of brain cancer called glioblastoma multiforme (GBM), there’s one fact that typically leaps out: It’s deadly. Newly-diagnosed patients have an overall survival rate of just 15 months. Even now, in 2018, the treatment landscape is sparse.

We readily talk about these dire prognoses in the media and on websites to stress the need for funding and better therapies. But it’s one thing to read about poor cancer survival rates and it’s another to have it applied to your own life. …

William Hearl

Dr. William Hearl is the founder & CEO of Immunomic Therapeutics, a clinical-stage biotech company developing novel immunotherapies for cancers and allergies

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store